Lumeon secures $28M in funding to accelerate growth in the US market - Gilde Healthcare

Lumeon secures $28M in funding to accelerate growth in the US market

December 4, 2018

Utrecht (The Netherlands), Boston (United States) – Lumeon, the digital health scale-up in Care Pathway Management (CPM), today announced the closure of a $28M investment. The financing allows Lumeon to expand its U.S. team and Boston headquarters, scale commercial operations and accelerate customer deployments in the region.
 
Along with LSP as lead investor, the finance was provided by MTIP and current investors Gilde, Amadeus Capital Partners, IPF Partners and Cedars-Sinai Medical Center.

 

About Lumeon
Lumeon enables healthcare organizations to orchestrate and automate systems and processes, bringing situational awareness to care operations to deliver high performance, team-centered healthcare. The industry-leading Lumeon Care Pathway Management (CPM) platform and suite of solutions empower health organizations to take control of their end-to-end care delivery model and maximize the use of resources. By iteratively designing and deploying efficient pathways, organizations reduce cost and minimize unwarranted variation, while flexibly adapting to emerging needs.
 
With headquarters in the USA and Europe, Lumeon serves some of the largest health enterprises across the globe, managing over six million patients on its platform. Find out more at www.lumeon.com.
 
About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a private equity fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022